Ovarian carcinoma (high-grade serous predominant) · line 1 · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`None`

ID	`IND-OVARIAN-MAINT-BEV`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-OVARIAN`
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. line_of_therapy: 1 because bev maintenance is continuation of 1L pathway. Missing entity flag: dedicated REG-BEV-MAINTENANCE-OVARIAN — author in PROD-2.

Used By

Handbook Chapters

HB-OVARIAN-MAINTENANCE-1L - Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning